<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04981379</url>
  </required_header>
  <id_info>
    <org_study_id>COVID-19-FAV-HQ</org_study_id>
    <nct_id>NCT04981379</nct_id>
  </id_info>
  <brief_title>Clinical Trial For Early SARS-CoV-2 (COVID-19) Treatment</brief_title>
  <official_title>Efficacy and Safety of the Use of Hydroxychloroquine, Favipiravir or Hydroxychloroquine + Favipiravir in Early SARS-CoV-2 (COVID-19) Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Health Institutes of Turkey</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Health Institutes of Turkey</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a randomized, double-blinded, and placebo controlled phase III clinical trial&#xD;
      which aims to investigate the superiority of hydroxychloroquine, favipiravir or&#xD;
      hydroxychloroquine + favipiravir treatment, initiated especially in the early period in the&#xD;
      treatment of COVID-19, over the patients being followed up with placebo in adults aged 18~59&#xD;
      Years.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a randomized, double-blinded, and placebo controlled phase III clinical trial&#xD;
      in in adults aged 18~59 Years. The study was planned as a multicenter, randomized controlled,&#xD;
      double-blind, parallel-arm drug study. The purpose of this study is to evaluate the efficacy&#xD;
      and safety of hydroxychloroquine, favipiravir, or hydroxychloroquine + favipiravir treatments&#xD;
      that were initiated early in patients who were caught during filiation or who were decided to&#xD;
      be outpatient due to mild disease findings during hospital admission, after the diagnosis of&#xD;
      COVID-19 against patients with placebo. It is planned that the study will be conducted with&#xD;
      two separate arms. Study arms are planned as 2:2:2:1 for 320:320:320:160 patients as follows.&#xD;
      The dose of Favipiravir has been determined as the standard dose. Hydroxychloroquine will&#xD;
      also be given without a loading dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 16, 2020</start_date>
  <completion_date type="Actual">February 16, 2021</completion_date>
  <primary_completion_date type="Actual">January 31, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomized, Double-Blind, Placebo-Controlled Phase III Clinical Trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
    <masking_description>Double-Blind</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Worsening of clinical findings</measure>
    <time_frame>During the study</time_frame>
    <description>Worsening of clinical findings such as respiratory distress or persistence of fever, which require hospital admission to begin another treatment (for example, remdesivir, dexamethasone, anti-cytokines, etc.)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Complete resolution of symptoms and signs</measure>
    <time_frame>Fifth day after examination</time_frame>
    <description>Complete resolution of symptoms and signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete resolution of symptoms and signs</measure>
    <time_frame>Tenth day after examination</time_frame>
    <description>Complete resolution of symptoms and signs</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative RT-PCR test for SARS-CoV-2</measure>
    <time_frame>Tenth day after examination</time_frame>
    <description>Negative RT-PCR test for SARS-CoV-2 virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of IgM, IgG levels for SARS-CoV-2</measure>
    <time_frame>Tenth day after examination</time_frame>
    <description>Determination of IgM, IgG levels for SARS-CoV-2 virus</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative RT-PCR test for SARS-CoV-2</measure>
    <time_frame>Thirtieth day after examination</time_frame>
    <description>Negative RT-PCR test for SARS-CoV-2 on the 30th day visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Determination of IgM, IgG antibodies</measure>
    <time_frame>Thirtieth day after examination</time_frame>
    <description>Determination of IgM, IgG antibodies against SARS-CoV-2</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development of signs of pneumonia</measure>
    <time_frame>During the study</time_frame>
    <description>Development of signs of pneumonia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of respiratory support with oxygen mask</measure>
    <time_frame>During the study</time_frame>
    <description>Requirement of respiratory support with oxygen mask</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of respiratory support with high flow oxygen</measure>
    <time_frame>During the study</time_frame>
    <description>Requirement of respiratory support with high flow oxygen</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Requirement of mechanical ventilation</measure>
    <time_frame>During the study</time_frame>
    <description>Requirement of mechanical ventilation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>During the study</time_frame>
    <description>Death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The rate of discontinuation of treatments due to side effects</measure>
    <time_frame>During the study</time_frame>
    <description>The rate of discontinuation of treatments due to side effects (gastrointestinal, allergic skin rash, arrhythmia, other cardiac reasons)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to improvement of symptoms after the initiation of study drugs</measure>
    <time_frame>During the study</time_frame>
    <description>Time to improvement of symptoms after the initiation of study drugs</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">1120</enrollment>
  <condition>Covid19</condition>
  <arm_group>
    <arm_group_label>Hydroxychloroquine + Favipiravir</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine 2x200 mg 5 days and favipiravir 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Favipiravir + Placebo (Hydroxychloroquine)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Favipiravir 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days) + Placebo (Hydroxychloroquine ) 2x200 mg (5 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Hydroxychloroquine + Placebo (Favipiravir)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Hydroxychloroquine 2x200 mg (for 5 days) + placebo (favipiravir) 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (Favipiravir) + Placebo (Hydroxychloroquine)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (favipiravir) 2 x 1600 mg loading, then 4 days 2 x 600 mg maintenance (5 days) + Placebo (Hydroxychloroquine) 2x200 mg (5 days)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Hydroxychloroquine</intervention_name>
    <description>Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval + Placebo [Favipiravir (1600 mg)], as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval.</description>
    <arm_group_label>Hydroxychloroquine + Placebo (Favipiravir)</arm_group_label>
    <other_name>Hydroxychloroquine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir</intervention_name>
    <description>Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Placebo [Hydroxychloroquine (200 mg)], as two tablets per day for 5-day interval.</description>
    <arm_group_label>Favipiravir + Placebo (Hydroxychloroquine)</arm_group_label>
    <other_name>Favicovir Film Tablet</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Favipiravir + Hydroxychloroquine</intervention_name>
    <description>Favipiravir (1600 mg), as two tablet per day at the first day and then Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.</description>
    <arm_group_label>Hydroxychloroquine + Favipiravir</arm_group_label>
    <other_name>Favicovir Film Tablet + Hydroxychloroquine sulfate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo [Favipiravir (1600 mg)], as two tablet per day at the first day and then Placebo Favipiravir (600 mg) as two tablet per day for the remaining 4-day interval + Hydroxychloroquine (200 mg), as two tablets per day for 5-day interval.</description>
    <arm_group_label>Placebo (Favipiravir) + Placebo (Hydroxychloroquine)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteers who have understood all the procedures to be applied within the scope of&#xD;
             the study protocol and gave their consent.&#xD;
&#xD;
          2. Patients between 18-60 years old.&#xD;
&#xD;
          3. Patients whose symptoms and complaints associated with COVID-19 started within 48&#xD;
             hours.&#xD;
&#xD;
          4. Mild cases whose treatment to be given as outpatient.&#xD;
&#xD;
               1. Although asymptomatic, patients with high CRP (&gt; 20 mg/L) and/or lymphopenia&#xD;
                  (&lt;1000/mm3)&#xD;
&#xD;
               2. Patients with symptoms such as fever, muscle/joint pain, cough, sore throat,&#xD;
                  nasal congestion, loss of smell.&#xD;
&#xD;
               3. Patients without serious underlying diseases (cardiovascular diseases, diabetes&#xD;
                  mellitus, hypertension, cancer, chronic lung diseases, immunosuppressive&#xD;
                  conditions)&#xD;
&#xD;
               4. Patients with normal chest x-ray and / or chest tomography (no sign of pneumonia)&#xD;
&#xD;
          5. Patients who accept oropharyngeal sample and venous blood collection at regular&#xD;
             intervals within the scope of the protocol.&#xD;
&#xD;
          6. Patients who were not involved in any other interventional study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who do not give their consent in writing after informing.&#xD;
&#xD;
          2. Being under the age of 18 and over the age of 60.&#xD;
&#xD;
          3. Patients with a known history of allergy to one of the study drugs&#xD;
             (hydroxychloroquine, favipiravir).&#xD;
&#xD;
          4. Volunteers who the researcher thinks may have problems with adherence to treatment.&#xD;
&#xD;
          5. Volunteers who will have trouble taking medication by mouth due to resistant nausea,&#xD;
             vomiting or chronic diarrhea.&#xD;
&#xD;
          6. Patients with chronic liver disease and transaminase (ALT or AST) levels 5 times the&#xD;
             higher than the normal level.&#xD;
&#xD;
          7. Patients with heart disease or arrhythmia history.&#xD;
&#xD;
          8. Patients with gout or hyperuricemia.&#xD;
&#xD;
          9. Patients with signs of pneumonia in their lungs.&#xD;
&#xD;
         10. Patients with chronic renal failure (glomerular filtration rate &lt;30).&#xD;
&#xD;
         11. Pregnant or breastfeeding patients.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>59 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ahmet Gül, Prof.</last_name>
    <role>Study Director</role>
    <affiliation>Faculty Member</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ankara City Hospital</name>
      <address>
        <city>Ankara</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Başakşehir Çam ve Sakura City Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul Bakirkoy Dr. Sadi Konuk Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istanbul University Istanbul Medicine Faculty</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kartal Dr. Lütfi Kırdar City Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sancaktepe Şehit Prof. Dr. İlhan Varank Training and Research Hospital</name>
      <address>
        <city>Istanbul</city>
        <country>Turkey</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>McCullough PA. Favipiravir and the Need for Early Ambulatory Treatment of SARS-CoV-2 Infection (COVID-19). Antimicrob Agents Chemother. 2020 Nov 17;64(12). pii: e02017-20. doi: 10.1128/AAC.02017-20. Print 2020 Nov 17.</citation>
    <PMID>32967849</PMID>
  </reference>
  <reference>
    <citation>Shrestha DB, Budhathoki P, Khadka S, Shah PB, Pokharel N, Rashmi P. Favipiravir versus other antiviral or standard of care for COVID-19 treatment: a rapid systematic review and meta-analysis. Virol J. 2020 Sep 24;17(1):141. doi: 10.1186/s12985-020-01412-z.</citation>
    <PMID>32972430</PMID>
  </reference>
  <reference>
    <citation>Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, Mutoh Y, Homma Y, Terada M, Ogawa T, Kashizaki F, Yokoyama T, Koba H, Kasahara H, Yokota K, Kato H, Yoshida J, Kita T, Kato Y, Kamio T, Kodama N, Uchida Y, Ikeda N, Shinoda M, Nakagawa A, Nakatsumi H, Horiguchi T, Iwata M, Matsuyama A, Banno S, Koseki T, Teramachi M, Miyata M, Tajima S, Maeki T, Nakayama E, Taniguchi S, Lim CK, Saijo M, Imai T, Yoshida H, Kabata D, Shintani A, Yuzawa Y, Kondo M. A Prospective, Randomized, Open-Label Trial of Early versus Late Favipiravir Therapy in Hospitalized Patients with COVID-19. Antimicrob Agents Chemother. 2020 Nov 17;64(12). pii: e01897-20. doi: 10.1128/AAC.01897-20. Print 2020 Nov 17.</citation>
    <PMID>32958718</PMID>
  </reference>
  <reference>
    <citation>Hu TY, Frieman M, Wolfram J. Insights from nanomedicine into chloroquine efficacy against COVID-19. Nat Nanotechnol. 2020 Apr;15(4):247-249. doi: 10.1038/s41565-020-0674-9.</citation>
    <PMID>32203437</PMID>
  </reference>
  <reference>
    <citation>Boulware DR, Pullen MF, Bangdiwala AS, Pastick KA, Lofgren SM, Okafor EC, Skipper CP, Nascene AA, Nicol MR, Abassi M, Engen NW, Cheng MP, LaBar D, Lother SA, MacKenzie LJ, Drobot G, Marten N, Zarychanski R, Kelly LE, Schwartz IS, McDonald EG, Rajasingham R, Lee TC, Hullsiek KH. A Randomized Trial of Hydroxychloroquine as Postexposure Prophylaxis for Covid-19. N Engl J Med. 2020 Aug 6;383(6):517-525. doi: 10.1056/NEJMoa2016638. Epub 2020 Jun 3.</citation>
    <PMID>32492293</PMID>
  </reference>
  <reference>
    <citation>Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L, Hens B, Vergote V, Heylen E, Barthelemy K, Maas E, De Keyzer C, Bervoets L, Rymenants J, Van Buyten T, Zhang X, Abdelnabi R, Pang J, Williams R, Thibaut HJ, Dallmeier K, Boudewijns R, Wouters J, Augustijns P, Verougstraete N, Cawthorne C, Breuer J, Solas C, Weynand B, Annaert P, Spriet I, Vande Velde G, Neyts J, Rocha-Pereira J, Delang L. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci U S A. 2020 Oct 27;117(43):26955-26965. doi: 10.1073/pnas.2014441117. Epub 2020 Oct 9.</citation>
    <PMID>33037151</PMID>
  </reference>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 29, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>COVID-19</keyword>
  <keyword>Hydroxychloroquine</keyword>
  <keyword>Favipiravir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hydroxychloroquine</mesh_term>
    <mesh_term>Favipiravir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

